Please login to the form below
hypereosinophilic syndrome
This page shows the latest hypereosinophilic syndrome news and features for those working in and with pharma, biotech and healthcare.
Nucala works in rare inflammatory disease, says GSK
GlaxoSmithKline is eyeing another regulatory filing for its IL-5 inhibitor Nucala, after reporting positive phase 3 results with the drug in rare disease hypereosinophilic syndrome (HES).
Latest news
-
GSK starts trial of Nucala to seek alternate indications
levels of eosinophil white cells - including chronic obstructive pulmonary disease (COPD), severe atopic dermatitis, hypereosinophilic syndrome and eosinophilic granulomatosis with polyangiitis.
-
GSK's Nucala posts mixed results in COPD
To that end, GSK started a phase III study of Nucala in March in patients with severe hypereosinophilic syndrome (HES), which can result in organ damage and get progressively more severe
-
GSK’s new asthma biologic gains FDA panel backing
GSK originally developed mepolizumab as a treatment for a rare and sometimes fatal condition called hypereosinophilic syndrome (HES), but withdrew its marketing application for this indication in 2009 in EU after ... The antibody is being investigated in
-
GSK set to file severe asthma candidate by year-end
GSK originally developed mepolizumab as a treatment for a rare and sometimes fatal condition called hypereosinophilic syndrome (HES), but withdrew its marketing application for this indication in 2009 in EU after ... The antibody is being investigated in
-
Novartis withdraws application for Ruvise approval in EU
diseases, advanced hypereosinophilic syndrome and dermatofibrosarcoma protuberans.
More from news
Approximately 1 fully matching, plus 6 partially matching documents found.
Latest Intelligence
-
Exploring the potential of eosinophils
eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES).
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Novo Nordisk and Valo Health agree deal worth up to $3.3bn
- Landscape review reveals £1.1bn of UK funding for rare diseases
- Cancer Research UK partners with French cancer institute
- New diagnosis pathway has been launched to mark European Myeloma Day
- Impacting Lives with Rare Disease Education
- Sandoz biosimilar receives EC approval to treat MS
No results were found
PMHub
An agency called Owen
We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
